EHS Syngeneic Model Service for Sarcoma

The EHS syngeneic model is a transplantable mouse sarcoma platform distinguished by its extraordinary production of basement membrane components, offering a uniquely matrix-rich setting for preclinical sarcoma research. Alfa Cytology delivers comprehensive preclinical support around the EHS model, covering authenticated tumor material, model construction, treatment studies, and microenvironment-focused readouts, giving your sarcoma program a dependable foundation for decision-ready data.

Overview of EHS Syngeneic Model for Sarcoma

The Engelbreth-Holm-Swarm (EHS) sarcoma is a transplantable, undifferentiated mouse tumor first described in the 1930s and maintained ever since by serial passage in genetically matched hosts. Because the tumor grows in syngeneic C57BL/6 mice, experiments with EHS are performed in vivo in animals that retain a complete immune system, avoiding the immunological distortion of xenograft systems. What sets EHS apart from virtually every other sarcoma model is its massive secretion of basement membrane proteins: EHS cells are the source of laminin, type IV collagen, entactin, and heparan sulfate proteoglycan (perlecan), and extracts of the EHS tumor are used worldwide to manufacture Matrigel and related basement membrane preparations. The tumor therefore grows as an extracellular matrix–rich mass in which tumor cells, stromal elements, and vasculature coexist much as they do in a genuine tumor microenvironment.

Fig 1. Chromosome painting karyotyping of EHSPEL cells derived from the EHS sarcoma reveals extensive interchromosomal rearrangements and partial hyperploidy, consistent with a highly rearranged sarcoma genome propagated through serial transplantation in syngeneic hosts. (Hayashi, Yoshitaka, et al., 2004)

These properties give the EHS syngeneic model a dual research value. First, it serves as a living system for studying tumor–matrix biology, including basement membrane assembly, matrix remodeling, and the barrier function of dense stroma against drug penetration, processes that conventional in vitro monolayers fail to reproduce. Second, its ECM-rich, moderately growing tumors are well suited to in vivo interrogation of tumor angiogenesis, stromal targeting strategies, and immunomodulatory therapies in a fully immunocompetent host. The establishment of a cultured cell line from the EHS tumor (ATCC CRL-2108, reported in 1992) further expanded the toolkit, enabling standard cell-based manipulation followed by re-implantation into C57BL/6 mice, as well as the widely used Matrigel plug angiogenesis assay in which EHS-derived matrix supports neovessel formation.

Cell Line Information: EHS

EHS (Engelbreth-Holm-Swarm sarcoma) is a murine tumor-derived line propagated in syngeneic mice, with a cultured derivative available for experimental work. Key attributes are summarized below.

Our Services

From quality-controlled tumor material through customized study execution, Alfa Cytology brings disciplined, preclinical-grade operations to every EHS syngeneic engagement, so your sarcoma studies proceed with reproducible tumors and interpretable results.

Workflow of EHS Syngeneic Model Construction

Constructing an EHS syngeneic model follows a clear, quality-driven sequence that adapts to whether the study starts from cultured cells or from transplantable tumor fragments.

1. Tumor material quality control: EHS cells or tumor fragments are checked for mycoplasma and confirmed for identity before use, and cultured material is kept at low passage to preserve growth behavior.
2. Inoculum preparation: Cultured EHS cells are detached, washed, and resuspended in sterile PBS at the target concentration; when fragment-derived implantation is preferred, fresh tumor tissue is aseptically minced into small pieces of uniform size.
3. Host mouse preparation: Syngeneic C57BL/6 mice, typically 6–8 weeks of age, are acclimatized, examined for baseline health, and documented before any manipulation.
4. Tumor implantation: Cell suspensions or tumor fragments are implanted subcutaneously into the flank; where matrix-supported growth is desired, cells may be mixed with EHS-derived basement membrane extract before injection.
5. Tumor monitoring and randomization: Tumor dimensions are measured with digital calipers two to three times per week, with volume calculated as (length × width²) / 2; animals enter treatment arms once tumors reach the predefined size range.
6. Dosing and tolerability: Test agents, vehicles, or combinations are administered on the study schedule, and in vivo safety is followed through body weight, clinical observations, and predefined welfare criteria.
7. Endpoint analysis and reporting: Tumors are excised and weighed; optional readouts include immunohistochemistry for laminin and type IV collagen, CD31 staining for microvessel density, flow cytometric profiling of infiltrating immune cells, and histopathological review, compiled into a complete statistical report.

Fig 2. EHS Syngeneic Model construction workflow.

Case Study-EHS Syngeneic Model Development

Alfa Cytology has executed a variety of preclinical programs on the EHS syngeneic platform, spanning stromal and angiogenesis-focused treatment concepts, matrix-targeting agents, and immunomodulatory combinations. Each engagement is configured around the sponsor’s scientific questions, with adjustable implantation formats, dosing schemes, and endpoint panels, and representative program overviews are available on request.

Why Choose Alfa Cytology?

For the EHS syngeneic model, Alfa Cytology pairs specialized knowledge of matrix-rich sarcoma biology with rigorous operational standards.

• Verified EHS tumor material with documented identity and mycoplasma screening at study start.
• Hands-on experience with ECM-rich syngeneic tumors, where stromal density shapes both growth kinetics and drug exposure in vivo.
• Adaptable implantation options, including cell suspension, tumor fragment, and basement membrane extract–supported formats.
• Integrated in vitro and in vivo workflows that connect cell-level findings to whole-tumor outcomes.
• Matrix-aware endpoint capabilities, from collagen and laminin staining to microvessel density quantification.
• Transparent project communication and compliance with preclinical animal care requirements from initiation to final report.

Contact Us

If your sarcoma research requires a matrix-rich, immunocompetent model, please contact us to explore how the EHS platform can fit your program. Our specialists at Alfa Cytology are ready to reach out with a customized plan for your next preclinical study.

For research use only. Not intended for any clinical use.